Table 3. Summary of clinical outcomes of various OVs in different neoplastic disorders.
mOS: median overall survival, ORR: objective response rate, CR: complete response, OR: objective response , DIPG: diffuse intrinsic pontine glioma, pCR: pathological complete response, PR: partial response, SD: stable disease, GBM: glioblastoma multiforma, MG: malignant glioma, AA: anaplastic astrocytoma, RE: recurrent ependymoma, AEs: adverse events, PFS: progression free survival, HNSCC: hand and neck squamous cell carcinoma, NSCLC: non-small cell lung carcinoma, MPM: malignant pleural mesothelioma, CRC: colorectal cancer, LAPC: local advanced pancreatic cancer, HCC: hepatocellular carcinoma, mBC: metastatic breast cancer, PROC: platinum resistant ovarian cancer, CRPC: castrate-resistent prostatic cancer, RCC: renal cell carcinoma, CBCL: cutaneous B cell lymphoma, CLL: chronic lymphocytic leukemia.
| Cancer | Virus | Participants | Clinical outcomes | Reference |
| Melanoma | T-VEC | 436 | Improved longer-term efficacy and overall survival (mOS 23.3 months, ORR 31.5%, and CR 16.9%) | [45] |
| PVSRIPO | 12 | OR: 33%, pCR in two patients, no progression in 50% in 18 months | [47] | |
| Poxvirus | 1 | Clinical regression of the lesion with grade ½ AEs | [106] | |
| Pediatric DIPG | DNX-2401 | 12 | mOS 17,8 months, Reduction in tumor size in 75%, PR: 25%, SD: 67%, 2 patients achieved 3 years-survival. | [49] |
| GBM | G47∆ | 19 | mOS: 20.2 months, 1-year survival in 84.2%, PR: 1 patient, SD: 18 patients, | [52] |
| Reolysin | 15 | mOS: 13.1 months, 2-year survival in 33%. | [54] | |
| Pediatric MG, AA, and RE | AdV-tk | 8 | 2-year survival: 37.5%, 2 patients > 36 months, AEs: Grade 1/2 | [55] |
| HNSCC | GL-ONC1 | 19 | PFS in 1st year: 74.7% and in 2nd year: 64.1% OS in 1st year: 84.6%, 2nd year: 69.2% | [57] |
| T-VEC | 36 | ORR: 16.7%, six paitents had PR and 8 patients had SD. | [58, 59] | |
| rAd-p53 | 102 | Improved OS and disease-free survival rates | [60] | |
| NSCLC | TG4010 | 222 | Improved PF survival among TG4010 compared to placebo, only 4% had grade 3/4 AEs . | [62] |
| MEM-288 | 11 | No DLTs. SD: 2 patients and PD: 5 patients. | [107] | |
| MPM | HSV1716 | 12 | SD: 50% | [65] |
| Esophageal cancer | OBP-301 | 13 | ORR: 91.7%, CR: 61.5%, PR: 13% | [66] |
| CRC | Reolysin | 30 | PR: 20%, SD: 73.3%, mOS: 25.1 months | [67] |
| OH2 | 54 (35 with CRC) | SD: 13 patients, PR: 2 patients, Tumor with lymph node metastasis regression in 2 patients | [69] | |
| LAPC | HF10 | 9 | PR: 33%, SD: 44%, mOS: 15.1 months | [71] |
| Ad5-DS | 9 | SD: eight patients, PR: one patient, median PFS: 11.4 months. | [73] | |
| Reolysin | 10 | Disease control in 3 patients: 1 PR for 17.4 months, 2 SD for 9 and 4 months. Grade 1-2 AEs. | [108] | |
| HCC | AdV-tk | 77 | Improved 5-year survival | [76] |
| JX-594 | 30 | Improved OS with CR in one patient | ||
| mBC | AdV-tk | 28 | Clinical benefit: 21.43%, PR: 1 patient, SD: 3 patients, CR: 2 patients (1 patient remains disease-free for 39 months). | [79] |
| T-VEC | 9 | pCR: 55% with lymph node metastasis regression in 3 patients, | [80] | |
| Reolysin | 74 | Improved mOS: 17.4 months | [109] | |
| PROC | Olvi-Vec | 12 | SD: 64%, Improved OS in 3 patients > 30 months, | [83] |
| enadenotucirev | 38 | SD: 35%, reduction in tumor burden in 65% | [84] | |
| CRPC | GEN0101 | 9 | SD: 67% and reduction of lymph node metastasis in 3 patients | [90] |
| AdV PSA/MUC1/brachyury | 18 | SD: 5 patients, PR: 1 patient, Notable decline in PSA levels. | [91] | |
| Bladder cancer | CG0070 | 35 | CR in 6, 12, and 18 months: 44%, 30%, and 23% respectively | [94, 95] |
| Nadofaragene firadenovec | 157 | Improved 2-year survival rate | [97] | |
| RCC | Pexa-Vec | 16 | Tumor reduction and overall disease control 75% | [98] |
| CBCL | TG1042 | 11 | CR: 63.6% and PR: 36.4% | [103] |
| CLL | Ad-ISF35 | 15 | PR: 20%, SD: 46.7%, with reduction in lymphadenopathy and splenomegaly | [105] |